The reduction in T1DM mortality likely stems from advancements in insulin therapy, continuous glucose monitoring, and structured patient education, which have improved glycemic control and reduced acute complications like diabetic ketoacidosis (7). This evidence concerns the gene INS and type 1 diabetes mellitus.